Autolus Therapeutics plc (AUTL) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Autolus Therapeutics plc (AUTL) Bundle
Designed for accuracy, our (AUTL) DCF Calculator enables you to evaluate Autolus Therapeutics plc's valuation using real-world financial data, offering complete flexibility to modify all key parameters for enhanced predictions.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 2.9 | .2 | 2.3 | 6.2 | 1.7 | 1.8 | 2.0 | 2.2 | 2.4 | 2.6 |
Revenue Growth, % | 0 | -91.68 | 862.81 | 165.84 | -72.59 | 8.93 | 8.93 | 8.93 | 8.93 | 8.93 |
EBITDA | -134.4 | -160.5 | -132.0 | -135.5 | -156.8 | -1.8 | -2.0 | -2.2 | -2.4 | -2.6 |
EBITDA, % | -4621.63 | -66325.62 | -5665.49 | -2188.18 | -9232.63 | -100 | -100 | -100 | -100 | -100 |
Depreciation | 4.6 | 5.7 | 8.5 | 7.4 | 6.6 | 1.8 | 2.0 | 2.2 | 2.4 | 2.6 |
Depreciation, % | 158.56 | 2375.62 | 366.87 | 119.83 | 386.63 | 100 | 100 | 100 | 100 | 100 |
EBIT | -139.0 | -166.3 | -140.6 | -143.0 | -163.3 | -1.8 | -2.0 | -2.2 | -2.4 | -2.6 |
EBIT, % | -4780.19 | -68701.24 | -6032.36 | -2308.01 | -9619.26 | -100 | -100 | -100 | -100 | -100 |
Total Cash | 210.6 | 153.3 | 310.3 | 382.4 | 239.6 | 1.8 | 2.0 | 2.2 | 2.4 | 2.6 |
Total Cash, percent | .0 | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | 30.5 | 29.7 | .1 | .2 | 1.0 | 1.0 | 1.1 | 1.2 | 1.3 | 1.4 |
Account Receivables, % | 1049.66 | 12266.53 | 2.92 | 2.47 | 61.66 | 53.41 | 53.41 | 53.41 | 53.41 | 53.41 |
Inventories | 7.8 | -29.7 | 10.1 | 14.2 | .0 | .7 | .8 | .9 | 1.0 | 1.0 |
Inventories, % | 268.57 | -12266.53 | 434.51 | 228.54 | 0 | 40 | 40 | 40 | 40 | 40 |
Accounts Payable | 1.1 | 2.3 | .4 | .5 | .1 | .6 | .7 | .7 | .8 | .9 |
Accounts Payable, % | 36.97 | 935.12 | 18.5 | 8.57 | 6.07 | 34.02 | 34.02 | 34.02 | 34.02 | 34.02 |
Capital Expenditure | -18.7 | -14.7 | -8.9 | -10.8 | -11.0 | -1.8 | -2.0 | -2.2 | -2.4 | -2.6 |
Capital Expenditure, % | -641.95 | -6066.53 | -380.13 | -175.02 | -647 | -100 | -100 | -100 | -100 | -100 |
Tax Rate, % | 0.009117 | 0.009117 | 0.009117 | 0.009117 | 0.009117 | 0.009117 | 0.009117 | 0.009117 | 0.009117 | 0.009117 |
EBITAT | -123.8 | -142.1 | -120.3 | -122.8 | -163.3 | -1.7 | -1.8 | -2.0 | -2.1 | -2.3 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -175.2 | -111.5 | -132.7 | -130.3 | -154.9 | -1.8 | -1.9 | -2.1 | -2.2 | -2.5 |
WACC, % | 21.4 | 21.04 | 21.05 | 21.08 | 22.5 | 21.42 | 21.42 | 21.42 | 21.42 | 21.42 |
PV UFCF | ||||||||||
SUM PV UFCF | -5.9 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | -2 | |||||||||
Terminal Value | -13 | |||||||||
Present Terminal Value | -5 | |||||||||
Enterprise Value | -11 | |||||||||
Net Debt | -187 | |||||||||
Equity Value | 176 | |||||||||
Diluted Shares Outstanding, MM | 174 | |||||||||
Equity Value Per Share | 1.01 |
What You Will Get
- Real AUTL Financial Data: Pre-filled with Autolus Therapeutics' historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Autolus Therapeutics' intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive AUTL Data: Pre-loaded with Autolus Therapeutics' historical financials and future projections.
- Fully Customizable Inputs: Modify revenue growth, profit margins, discount rates, tax implications, and capital investments.
- Dynamic Valuation Model: Automatic recalculations of Net Present Value (NPV) and intrinsic value based on your adjustments.
- Scenario Analysis: Generate various forecasting scenarios to evaluate different valuation results.
- User-Friendly Interface: Intuitive, organized, and crafted for both professionals and newcomers.
How It Works
- Download the Template: Gain immediate access to the Excel-based AUTL DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and additional parameters.
- Instant Calculations: The model automatically recalculates Autolus Therapeutics' intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the results to inform your investment or financial analysis.
Why Choose This Calculator for Autolus Therapeutics (AUTL)?
- User-Friendly Interface: Tailored for both novices and seasoned professionals.
- Customizable Inputs: Adjust parameters easily to suit your financial analysis.
- Real-Time Valuation: Observe immediate updates to Autolus’s valuation as you change the inputs.
- Preloaded Data: Comes equipped with Autolus's actual financial metrics for swift evaluations.
- Relied Upon by Experts: Utilized by investors and analysts for making well-informed choices.
Who Should Use Autolus Therapeutics plc (AUTL)?
- Investors: Gain insights into innovative therapies and make informed investment choices.
- Healthcare Analysts: Utilize comprehensive data to evaluate the potential of cutting-edge treatments.
- Consultants: Tailor reports and presentations quickly using the latest research from Autolus Therapeutics.
- Biotech Enthusiasts: Expand your knowledge of advanced cell therapies and their market impact.
- Educators and Students: Leverage real-world case studies to enhance learning in biotechnology and pharmaceuticals.
What the Template Contains
- Historical Data: Includes Autolus Therapeutics plc’s past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Autolus Therapeutics plc’s intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Autolus Therapeutics plc’s financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.